|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
|
31620934 |
2020 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Evaluating the genetic alterations from METABRIC and TCGA datasets, we then assessed that FGFR1 is the most frequently amplified FGFRs family member and its amplification/expression associates with shorter survival rates in breast cancer patients.
|
30866584 |
2019 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In sum, C11 is a novel selective FGFR1 inhibitor that exhibits potent activity against breast cancer metastasis and angiogenesis.
|
30487650 |
2019 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Immunological histological chemistry (IHC) assays were carried out to detect the expression levels of fibroblast growth factor receptor 1 (FGFR1) in BC tissue samples.
|
31841196 |
2019 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings suggest that FGFR1 alternative FGFR1α/FGFR1β splicing plays an important role in breast cancer.
|
30713601 |
2019 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this study, we analyzed possible impact of 8 genetic variants of fibroblast growth factor receptor1-4 (FGFR1-4) on the treatment response and toxicities in 211 breast cancer patients.
|
30359238 |
2018 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We found that BGJ398, an FGFR inhibitor, effectively inhibited phosphorylation of FGFR1 and MEK/ERK signaling in FGFR1-amplified breast cancer without affecting tumor cell proliferation.
|
29970903 |
2018 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, we found using Bayesian network-based machine learning that 30 NRF1 motif-enriched genes including growth factor receptors-FGFR1, IGF1R; E2Fs transcription factor family-E2F1, E2F3; MAPK pathway-SHC2, GRB2, MAPK1; PI3K-AKT-mTOR signaling pathway-PIK3CD, PIK3R1, PIK3R3, RPS6KB2; WNT signaling pathway-WNT7B, DLV1, DLV2, GSK3B, NRF1, and DDB2, known for its role in DNA repair and involvement in early events associated with metastatic progression of breast cancer cells, were associated with HER2-amplified breast cancer.
|
30128822 |
2018 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The minor allele of rs17182023 in FGFR1 was significantly associated with reduced breast cancer risk, with an odds ratio of 0.800 (95%CI = 0.684-0.935).
|
29996114 |
2018 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
As FGF2 and FGFR1 are implicated in breast cancer progression, we hypothesize that VAT-derived FGF2 plays a translational role in promoting adiposity-associated mammary epithelial cell transformation.
|
29561195 |
2018 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our results suggest that FGFR1 signaling is a key pathway driving breast cancer lung metastasis and that targeting FGFR1 in breast cancer is an exciting approach to inhibit metastasis.
|
28433771 |
2017 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray.
|
28125801 |
2017 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Lucitanib is a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptors 1 to 3 (VEGFR1 to 3), platelet derived growth factor α/β (PDGFRα/β) and FGFR1-3 tyrosine kinases and has demonstrated activity in a phase I/II clinical study, with objective RECIST responses in breast cancer patients with FGFR1 or FGF3/4/19 gene amplification, as well as in patients anticipated to benefit from anti-angiogenic agents.
|
27988457 |
2017 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
ER<sup>+</sup>/<i>FGFR1</i>-amplified breast cancer cells, and patient-derived xenografts (PDX) were treated with FGFR1 siRNA or the FGFR tyrosine kinase inhibitor lucitanib.
|
28751448 |
2017 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Using both non-transformed and transformed cell lines, we demonstrate that breast cancer cells express a number of FGF ligands that are known to activate FGFR1.
|
28968431 |
2017 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
An inverse expression pattern was also found between miR-361-5p and FGFR1 or MMP-1 in a cohort of 60 BC tissues.
|
29132384 |
2017 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Metastatic pmucBC is a distinct form of breast cancer that features a relatively high frequency of CRGA, including a significant enrichment of FGFR1 alterations and a high frequency of ERBB2 alterations when compared with non-metastatic pmucBC.
|
26762307 |
2016 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Consistent with animal studies, we found that in human BCa bone metastatic tissues, TGF-β type II receptor (TβRII) and p-Smad2 were expressed in osteoclasts and tumor cells, and were correlated with the expression of FGFR1.
|
26279296 |
2016 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Overall, the level of FGFR1 protein expression may be a biomarker of ER-positive/HER2-negative primary breast cancer with possible resistance to standard treatment, and may be a useful tool to identify more specific patients who would benefit from FGFR-1 targeted therapy.
|
26801869 |
2016 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We evaluated FGFR1 expression in a large cohort of breast cancer by immunohistochemistry, correlated with the tumor clinic-pathologic features, biomarkers expression, and patient's survival.
|
26673008 |
2016 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Overall, the current studies demonstrate that FGFR1 works in concert with other EMT effector molecules to drive aberrant downstream signaling, and that these events can be effectively targeted using our novel therapeutics for the treatment of the most aggressive forms of breast cancer.
|
27371729 |
2016 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The mRNA and protein expression level of FGFR1 and other FGFRs were examined in several lines of breast cancer and osteosarcoma cells and corresponding normal cells using Taqman real-time quantitative PCR and Western blot analysis.
|
26201468 |
2015 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The results of our study strongly suggest that FGFR1-β is required for the pulmonary outgrowth of metastatic BC.
|
24618085 |
2014 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Dovitinib also inhibits tumor growth in FGFR1-amplified breast cancer xenografts.
|
23658459 |
2013 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to evaluate FGFR-1, -2, -3, and -4 protein expressions in normal murine mammary gland development, and in murine and human breast carcinomas.
|
22124578 |
2012 |